Investor Overview

Corporate Profile

vTv Therapeutics is a clinical stage biotechnology company committed to improving the lives of diabetes patients.

vTv has a pipeline of clinical drug candidates developed using our innovative technology and led by our TTP399 program for the treatment of type 1 diabetes. vTv’s development partners are pursuing additional indications in type 2 diabetes, chronic obstructive pulmonary disease, psoriasis, atopic dermatitis, renal disease, primary mitochondrial myopathy, and pancreatic cancer.

More >>

Recent News

Date Title
Toggle Summary Elizabeth Keiley Selected as Executive Vice President and General Counsel of vTv Therapeutics
HIGH POINT, N.C. , Feb. 01, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D), today announced the appointment of Elizabeth (Betzy) Keiley as Executive Vice
View HTML
Toggle Summary vTv Therapeutics Appoints Biotech Industry Veteran Steven Tuch as Chief Financial Officer
Steven Tuch , Chief Financial Officer HIGH POINT, N.C. , Dec. 13, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D), today announced the appointment of
View HTML
Toggle Summary vTv Therapeutics Announces 2022 Third Quarter Financial Results and Provides Corporate Update
Company on-track to initiate Phase 3 clinical trials of TTP399 in the first quarter of 2023 Industry veteran Paul Sekhri joins the Company as President, Chief Executive Officer, and member of the Board of Directors Agreements with CinRx Pharma and a subsidiary to provide additional capital and
View HTML
Toggle Summary vTv Therapeutics Announces 2022 Second Quarter Financial Results and Provides Corporate Update
Paul Sekhri appointed as President, Chief Executive Officer and Board member. Entered into agreements with CinRx Pharma and a subsidiary to purchase $10 million in stock and to leverage CinRx’s industry experience to collaborate in overseeing TTP399 clinical trials.
View HTML
More >>
Upcoming Events
More events are coming soon.

Receive E-mail Alerts

Click here to sign up to receive e-mail alerts whenever vTv Therapeutics Inc. posts new information to the site.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.